Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab for Patients With Giant Cell Arteritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly onset or relapsed GCA~* \> 50 years of age~* satisfying ACR criteria~* elevated sedimentation rate above 40 mm~* CRP \> 20 mg/L~* Patients with histologically proven GCA or with large vessel vasculitis assessed by MRI~Exclusion Criteria~* Rheumatic diseases (except for CPPD/chondrocalcinosis) other than GCA/Takayasu disease or polymyalgia rheumatica (i.e., RA, autoimmune connectivitides, other systemic vasculitides, a.o.)~* Evidence of significant and/or uncontrolled concomitant disease~* Diagnosis of GCA \> 4 weeks before screening visit and beginning of GC treatment \> 4 weeks before screening (only valid for new onset GCA), or when a patient received treatment with tocilizumab or with other biological agents (such as TNFα-blockers) within 3 months before screening~* Any condition or general state of health which, in the Investigator's opinion, would preclude participation in the study~* Actual or recent myocardial infarction (within the last 3 months before screening visit)~* Significant cardiac disease (NYHA Class III and IV), known severe chronic obstructive pulmonary disease (COPD) (FEV1 \< 50% predicted or Functional dyspnoea \> Grade 3 on the MRC Dyspnoea Scale) or other significant pulmonary disease~* Uncontrolled disease (such as asthma, psoriasis or inflammatory bowel disease) where flares are commonly treated with oral or injectable corticosteroids~* Known active infection of any kind, or any major episode of infection requiring hospitalization or treatment with i.v. anti-infectives within 4 weeks of baseline or completion of oral anti-infectives within 2 weeks prior to baseline~* History of deep space/tissue infection (e.g. fasciitis, abscess, osteomyelitis) within 52 weeks prior to baseline~* Any surgical procedure, including bone/joint surgery within 8 weeks prior to baseline or planned within the duration of the study~* History of serious recurrent or chronic infection (for screening for a chest infection a chest radiograph will be performed at screening if not performed within 12 weeks prior to screening)~* Lack of peripheral venous access~* Body weight \> 150 kg or BMI \> 35~* Previous treatment with tocilizumab or any other biological agent~* Treatment with any investigational agent within 28 days of screening or 5 half-lives of the investigational drug (whichever is the longer)~* History of severe allergic or anaphylactic reaction to any biologic agent or known hypersensitivity to any component of tocilizumab (RoActemra)~* Receipt of any vaccine within 28 days prior to baseline (a patient's vaccination record and need for immunization prior to receiving tocilizumab/placebo must be carefully investigated)~* Positive tests for hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HbcAb) or hepatitis C serology~* Positive Quantiferon-TB® test for latent Tb without subsequent INH prophylaxis~* Patients with active Tb which had to be treated for Tb within 2 years before the screening visit

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: EXPERIMENTAL): Tocilizumab 8mg/kg every 4 weeks until week 52.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo every 4 weeks until week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).